

Microsoft Bing

国内版

国际版

The management of HBV infection in patients with IBD under immu

Sign in

ALLIMAGESVIDEOSTOOLS

Ulcerative colitis with hepatitis B virus infection ...

<https://pubmed.ncbi.nlm.nih.gov/26876484>

Clinicians have strong concerns about using immunosuppressive therapies for IBD patients with hepatitis B virus (HBV) infection because aggressive immunosuppressive therapy can promote reactivation of HBV. For that reason, physicians hesitate to use steroids or other immunosuppressive drugs for IBD patients with HBV infection. **Granulocyte monocyte apheresis (GMA)** is a safe and effective therapy ...

Cited by: 1Author: Hisako Saito, Norio Hara/usa, Junko Kishi...

Publish Year: 2016

(PDF) Hepatitis B virus infection and immunosuppressive ...

<https://www.academia.edu/23242422>

The conventional immunosuppressive drugs used in the management of IBD patients include corticosteroids, thiopurines [azathioprine and 6-mercaptopurine], calcineurin inhibitors [cyclosporin and tacrolimus] and methotrexate.

PEOPLE ALSO ASK

What kind of disease can you get from HBV?

When does HBV reactivation occur in hepatitis B?

When do you need A hepatitis B booster?

See results for

Inflammatory Bowel Disease (Medical Condition)

A group of intestinal disorders that cause inflammation of the digestive tract.

Search Tools

Turn on Hover Translation (开悬词译)

ALL IMAGES VIDEOS

1,100,000 Results

Any time

Open links in new tab

**Review article: prevention and management of hepatitis B ...**<https://www.ncbi.nlm.nih.gov/pubmed/21416659>

AIM: To review the prevention and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in inflammatory bowel disease (IBD). METHODS: Bibliographical searches were performed in MEDLINE up to September 2010. RESULTS: The prevalence of both HBV and HCV infection in IBD patients is now similar to that of the general population.

Cited by: 138

Author: Javier P Gisbert, Maria Chaparro, Maria Est...

Publish Year: 2011

Viral hepatitis and inflammatory bowel disease<https://pubmed.ncbi.nlm.nih.gov/20480515>

Inflammatory bowel disease (IBD) patients with chronic hepatitis B virus (HBV) with active disease (elevated alanine aminotransferase level and viral replication) should receive HBV treatment. HBV reactivation is associated with significant morbidity and mortality in patients receiving immunosuppression. IBD patients may require long-term immunosuppression, and therefore should be ...

Cited by: 92

Author: Jason K. Hou, Fernando Velayos, Norah Ter...

Publish Year: 2010

Treatment with infliximab or azathioprine negatively ...<https://pubmed.ncbi.nlm.nih.gov/25967740>

Abstract. Background and aim: Immunization against hepatitis B virus (HBV) infection is recommended in patients with inflammatory bowel disease (IBD), particularly in those under immunosuppressive therapy. Limited data are available about IBD patient's response to HBV vaccination.

Cited by: 21

Author: Patricia Andrade, João Santos-Antunes, Su...

Publish Year: 2015

Clinical courses of chronic hepatitis B virus infection ...<https://pubmed.ncbi.nlm.nih.gov/22337144>

Background. Little is known about the clinical features of hepatitis B virus (HBV) infection in patients with inflammatory bowel disease (IBD). We therefore evaluated the influence of immunosuppressive treatment for IBD on the course of HBV infection and the effect of HBV infection on the therapeutic strategy and clinical course of IBD patients.

Cited by: 53

Author: Sang Hyoung Park, Suk-Kyun Yang, Young...

Publish Year: 2012


Hepatitis B and C viral infections screening in a Tunisian ...<https://pubmed.ncbi.nlm.nih.gov/33181811>**Search Tools**

Turn off Hover Translation (关闭翻译)

27 Apr 2021 09:13PM

11323 words • 67 matches • 41 sources

FAQ

 iThenticate®

63616_Auto_Edited-check.docx

Quoted Excluded
Bibliography Excluded

12%
Similarity

17

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 63616

Manuscript Type: REVIEW

Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

Axiaris G *et al.* HBV infection in IBD

Georgios Axiaris, Evanthia Zampeli, Spyridon Michopoulos, Giorgos Bamias

Abstract

Hepatitis B remains a significant global clinical problem, despite the implementation of safe and effective vaccination programs. The prevalence of hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD) largely follows the regional epidemiologic status. Serological screening with hepatitis B surface antigen (HBsAg), and antibodies to hepatitis B surface (anti-HBs) and core (anti-HBc) proteins is a key element in the management of IBD patients and, ideally, should be performed at IBD

Match Overview

1	Internet 35 words crawled on 20-Oct-2013 www.wjgnet.com	1%
2	Internet 91 words ink.springer.com	1%
3	Crossref 70 words Sirena Tripathyapong, K Rajender Reddy, "Hepatitis B Virus Reactivation", <i>Clinics in Liver Disease</i> , 2020	1%
4	Internet 44 words crawled on 13-Mar-2019 academic.oup.com	1%
5	Internet 31 words crawled on 18-Apr-2018 hepatoweb.com	<1%
6	Internet 26 words crawled on 23-Jun-2019 www.mdpi.com	<1%
7	Crossref 27 words "Hepatitis B Virus and Liver Disease", Springer Science and Business Media LLC, 2018	<1%
8	Internet 27 words crawled on 30-Apr-2020 scisearch.net	<1%
9	Internet 26 words crawled on 09-Apr-2018 www.jaypeejournal.com	<1%
10	Internet 23 words crawled on 09-Apr-2018 www.jaypeejournal.com	<1%

Text Only Report

PAGE: 1 OF 37

国内版

国际版

Management of hepatitis B virus infection in patients with inflamma



ALL

IMAGES

VIDEOS

407,000 Results

Any time ▾

Review article: prevention and management of hepatitis B ...

<https://www.ncbi.nlm.nih.gov/pubmed/21416659>

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Gisbert JP(1), Chaparro M, Esteve M. Author information: (1)Departme...

Cited by: 136

Author: Javier P Gisbert, Maria Chaparro, Maria E...

Publish Year: 2011

Clinical courses of chronic hepatitis B virus infection ...

<https://pubmed.ncbi.nlm.nih.gov/22337144>

Background: Little is known about the clinical features of hepatitis B virus (HBV) infection in patients with inflammatory bowel disease (IBD). We therefore evaluated the influence of immunosuppressi...

Cited by: 50

Author: Sang Hyoung Park, Suk-Kyun Yang, You...

Publish Year: 2012

INASL Guidelines on Management of Hepatitis B Virus ...

<https://pubmed.ncbi.nlm.nih.gov/30568345>

Hepatitis B Virus (HBV) reactivation in patients receiving chemotherapy, biologicals, immunosuppressants, or corticosteroids is emerging to be an important cause of morbidity and mortality...

Cited by: 10

Author: Anil Arora, Anil C. Anand, Ashish Kumar,...

Publish Year: 2018

Treatment with infliximab or azathioprine negatively ...

<https://pubmed.ncbi.nlm.nih.gov/25967740>

Abstract. Background and aim: Immunization against hepatitis B virus (HBV) infection is recommended in patients with inflammatory bowel disease (IBD), particularly in those under...

Cited by: 21

Author: Patrícia Andrade, João Santos-Antunes, ...

Publish Year: 2015

Challenges in treating patients with inflammatory bowel ...

<https://pubmed.ncbi.nlm.nih.gov/27718758>

Inflammatory bowel diseases (IBD) require long-term administration of immunomodulatory treatments to maintain disease remission. Due to the high worldwide prevalence of hepatitis B (HBV) or C (HCV)...

Cited by: 7

Author: Elisabetta Degenneri, Flavio Corbelli, Om...